首页> 外文期刊>Carcinogenesis >Serine threonine kinase 11/liver kinase B1 mutation in sporadic scirrhous-type gastric cancer cells
【24h】

Serine threonine kinase 11/liver kinase B1 mutation in sporadic scirrhous-type gastric cancer cells

机译:猪苏氨酸激酶11 /肝激酶B1致散氏乳酸型胃癌细胞中的突变

获取原文
获取原文并翻译 | 示例
           

摘要

Scirrhous-type gastric carcinoma (SGC), which is characterized by the rapid proliferation of cancer cells accompanied by extensive fibrosis, shows extremely poor survival. A reason for the poor prognosis of SGC is that the driver gene responsible for SGC has not been identified. To identify the characteristic driver gene of SGC, we examined the genomic landscape of six human SGC cell lines of OCUM-1, OCUM-2M, OCUM-8, OCUM-9, OCUM-12 and OCUM-14, using multiplex gene panel testing by next-generation sequencing. In this study, the non-synonymous mutations of serine threonine kinase 11/liver kinase B1 (STK11/LKB1) gene were detected in OCUM-12, OCUM-2M and OCUM-14 among the six SGC cell lines. Capillary sequencing analysis confirmed the non-sense or missense mutation of STK11/LKB1 in the three cell lines. Western blot analysis showed that LKB1 expression was decreased in OCUM-12 cells and OCUM-14 cells harboring STK11/LKB1 mutation. The mammalian target of rapamycin (mTOR) inhibitor significantly inhibited the proliferation of OCUM-12 and OCUM-14 cells. The correlations between STK11/LKB1 expression and clinicopathologic features of gastric cancer were examined using 708 primary gastric carcinomas by immunochemical study. The low STK11/LKB1 expression group was significantly associated with SGC, high invasion depth and frequent nodal involvement, in compared with the high STK11/LKB1 expression group. Collectively, our study demonstrated that STK11/LKB1 mutation might be responsible for the progression of SGC, and suggested that mTOR signaling by STK11/LKB1 mutation might be one of therapeutic targets for patients with SGC.
机译:Scirhous型胃癌(SGC)的特点是癌细胞快速增殖并伴有广泛纤维化,其生存率极低。SGC预后不良的一个原因是与SGC相关的驱动基因尚未确定。为了确定SGC的特征性驱动基因,我们通过下一代测序的多重基因面板测试,检测了六种人类SGC细胞系OCUM-1、OCUM-2M、OCUM-8、OCUM-9、OCUM-12和OCUM-14的基因组图谱。在这项研究中,在6个SGC细胞系的OCUM-12、OCUM-2M和OCUM-14中检测到丝氨酸苏氨酸激酶11/肝激酶B1(STK11/LKB1)基因的非同义突变。毛细管测序分析证实了三种细胞系中STK11/LKB1的无义或错义突变。Western blot分析显示,携带STK11/LKB1突变的OCUM-12细胞和OCUM-14细胞中LKB1的表达降低。雷帕霉素(mTOR)抑制剂的哺乳动物靶点显著抑制OCUM-12和OCUM-14细胞的增殖。采用免疫组化方法,对708例原发性胃癌进行STK11/LKB1表达与胃癌临床病理特征的相关性研究。与STK11/LKB1高表达组相比,STK11/LKB1低表达组与SGC、高浸润深度和频繁淋巴结受累显著相关。总之,我们的研究表明STK11/LKB1突变可能与SGC的进展有关,并提示STK11/LKB1突变产生的mTOR信号可能是SGC患者的治疗靶点之一。

著录项

  • 来源
    《Carcinogenesis》 |2020年第11期|共8页
  • 作者单位

    Osaka City Univ Mol Oncol &

    Therapeut Grad Sch Med Osaka 5458585 Japan;

    Osaka City Univ Mol Oncol &

    Therapeut Grad Sch Med Osaka 5458585 Japan;

    Osaka City Univ Mol Oncol &

    Therapeut Grad Sch Med Osaka 5458585 Japan;

    Osaka City Univ Dept Gastroenterol Surg Grad Sch Med Osaka 5458585 Japan;

    Osaka City Univ Mol Oncol &

    Therapeut Grad Sch Med Osaka 5458585 Japan;

    Osaka City Univ Mol Oncol &

    Therapeut Grad Sch Med Osaka 5458585 Japan;

    Osaka City Univ Mol Oncol &

    Therapeut Grad Sch Med Osaka 5458585 Japan;

    Osaka City Univ Mol Oncol &

    Therapeut Grad Sch Med Osaka 5458585 Japan;

    Osaka City Univ Mol Oncol &

    Therapeut Grad Sch Med Osaka 5458585 Japan;

    Osaka City Univ Mol Oncol &

    Therapeut Grad Sch Med Osaka 5458585 Japan;

    Tokyo Med Univ Dept Mol Pathol Tokyo 1608402 Japan;

    Osaka City Univ Dept Gastroenterol Surg Grad Sch Med Osaka 5458585 Japan;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 肿瘤学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号